Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expense - Debt (2021 - 2022)

Guided Therapeutics' Interest Expense - Debt history spans 2 years, with the latest figure at -$11503.0 for Q2 2022.

  • For Q2 2022, Interest Expense - Debt fell 200.0% year-over-year to -$11503.0; the TTM value through Jun 2022 reached $28094.0, changed N/A, while the annual FY2022 figure was $39597.0, 0.0% changed from the prior year.
  • Interest Expense - Debt for Q2 2022 was -$11503.0 at Guided Therapeutics, down from $39597.0 in the prior quarter.
  • Across five years, Interest Expense - Debt topped out at $39597.0 in Q1 2022 and bottomed at -$11503.0 in Q2 2022.